Takeda Uloric Cleared For Gout Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
Labeling for the xanthine oxidase inhibitor includes a Warning on cardiovascular safety, a concern of FDA’s.
You may also be interested in...
Takeda’s Uloric: CV Mortality Signal Leads US FDA To Ponder Regulatory Options
Advisory committee will discuss whether CARES postmarketing trial showing 34% increased risk of cardiovascular death for febuxostat warrants market withdrawal, use restrictions, or new labeling for the gout drug.
Savient Suggests More Restrictive REMS Plan For Pegloticase In BLA Amendment
PDUFA date shifts to July 30; FDA to reschedule advisory committee.
PPI Market Snapshot: Kapidex Joins The Party Fashionably Late
Undeterred by a crammed proton pump inhibitor market already filled with established brand drugs, low-cost generics and over-the-counter alternatives, Takeda is moving ahead with the launch of a new PPI, Kapidex (dexlansoprazole)